Redox regulation of cardiac hypertrophy

Journal of Molecular and Cellular Cardiology

Volumn 73, Issue , 2014, Pages 103-111

  Sag, Can M ^a   Santos, Celio X C ^a   Shah, Ajay M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiac; Hypertrophy; NADPH oxidase; Redox; Signaling

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); APOPTOSIS SIGNAL REGULATING KINASE 1; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTOCHROME P450 REDUCTASE; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN BINDING PROTEIN C; NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RYANODINE RECEPTOR 2; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA; TROPONIN I; XANTHINE; XANTHINE OXIDASE;

CALCIUM TRANSPORT; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; EXCITATION CONTRACTION COUPLING; FIBROSING ALVEOLITIS; HEART BLOOD VESSEL; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE VASCULARIZATION; HEART STRESS; HEART VENTRICLE HYPERTROPHY; HUMAN; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REGULATORY MECHANISM; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIOMEGALY; METABOLISM; PHYSIOLOGY;

ANIMALS; CARDIOMEGALY; HUMANS; NADPH OXIDASE; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84901852459     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.02.002     Document Type: Review

References (109)

1. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol 2000, 35:569-582.
2. Catalucci D., Latronico M.V., Ellingsen O., Condorelli G. Physiological myocardial hypertrophy: how and why?. Front Biosci 2008, 13:312-324.
3. Shiojima I., Sato K., Izumiya Y., Schiekofer S., Ito M., Liao R., et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005, 115:2108-2118.
4. Opie L.H., Commerford P.J., Gersh B.J., Pfeffer M.A. Controversies in ventricular remodelling. Lancet 2006, 367:356-367.
5. Burgoyne J.R., Mongue-Din H., Eaton P., Shah A.M. Redox signaling in cardiac physiology and pathology. Circ Res 2012, 111:1091-1106.
6. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424.
7. Giordano F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005, 115:500-508.
8. 2 accumulation for cell signaling. Cell 2010, 140:517-528.
9. Brewer A.C., Mustafi S.B., Murray T.V., Rajasekaran N.S., Benjamin I.J. Reductive stress linked to small HSPs, G6PD, and Nrf2 pathways in heart disease. Antioxid Redox Signal 2013, 18:1114-1127.
10. Li J.M., Gall N.P., Grieve D.J., Chen M., Shah A.M. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002, 40:477-484.
11. Takimoto E., Champion H.C., Li M., Ren S., Rodriguez E.R., Tavazzi B., et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005, 115:1221-1231.
12. Dai D.F., Johnson S.C., Villarin J.J., Chin M.T., Nieves-Cintron M., Chen T., et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ Res 2011, 108:837-846.
13. Xu X., Hu X., Lu Z., Zhang P., Zhao L., Wessale J.L., et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail 2008, 14:746-753.
14. Kowaltowski A.J., de Souza-Pinto N.C., Castilho R.F., Vercesi A.E. Mitochondria and reactive oxygen species. Free Radic Biol Med 2009, 47:333-343.
15. Bayeva M., Gheorghiade M., Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 2013, 61:599-610.
16. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Kang D., Hattori N., et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999, 85:357-363.
17. Conrad M., Jakupoglu C., Moreno S.G., Lippl S., Banjac A., Schneider M., et al. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol Cell Biol 2004, 24:9414-9423.
18. Stanley B.A., Sivakumaran V., Shi S., McDonald I., Lloyd D., Watson W.H., et al. Thioredoxin reductase-2 is essential for keeping low levels of H(2)O(2) emission from isolated heart mitochondria. J Biol Chem 2011, 286:33669-33677.
19. Dai D.F., Santana L.F., Vermulst M., Tomazela D.M., Emond M.J., MacCoss M.J., et al. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation 2009, 119:2789-2797.
20. Chin K.T., Kang G., Qu J., Gardner L.B., Coetzee W.A., Zito E., et al. The sarcoplasmic reticulum luminal thiol oxidase ERO1 regulates cardiomyocyte excitation-coupled calcium release and response to hemodynamic load. FASEB J 2011, 25:2583-2591.
21. Brandes R.P., Weissmann N., Schroder K. NADPH oxidases in cardiovascular disease. Free Radic Biol Med 2010, 49:687-706.
22. Brown D.I., Griendling K.K. Nox proteins in signal transduction. Free Radic Biol Med 2009, 47:1239-1253.
23. Santos C.X., Nabeebaccus A.A., Shah A.M., Camargo L.L., Filho S.V., Lopes L.R. Endoplasmic reticulum stress and nox-mediated reactive oxygen species signaling in the peripheral vasculature: potential role in hypertension. Antioxid Redox Signal 2014, 20:121-134.
24. Zhang M., Takimoto E., Lee D.I., Santos C.X., Nakamura T., Hsu S., et al. Pathological cardiac hypertrophy alters intracellular targeting of phosphodiesterase type 5 from nitric oxide synthase-3 to natriuretic peptide signaling. Circulation 2012, 126:942-951.
25. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003, 111:1201-1209.
26. Chen C.A., Wang T.Y., Varadharaj S., Reyes L.A., Hemann C., Talukder M.A., et al. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010, 468:1115-1118.
27. Kaludercic N., Carpi A., Menabo R., Di Lisa F., Paolocci N. Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta 1813, 2011:1323-1332.
28. Kaludercic N., Carpi A., Nagayama T., Sivakumaran V., Zhu G., Lai E.W., et al. Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal 2014, 20:267-280.
29. Lu D., Ma Y., Zhang W., Bao D., Dong W., Lian H., et al. Knockdown of cytochrome P450 2E1 inhibits oxidative stress and apoptosis in the cTnT(R141W) dilated cardiomyopathy transgenic mice. Hypertension 2012, 60:81-89.
30. Nishino T., Okamoto K., Eger B.T., Pai E.F., Nishino T. Mammalian xanthine oxidoreductase - mechanism of transition from xanthine dehydrogenase to xanthine oxidase. FEBS J 2008, 275:3278-3289.
31. Minhas K.M., Saraiva R.M., Schuleri K.H., Lehrke S., Zheng M., Saliaris A.P., et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 2006, 98:271-279.
32. Halliwell B.G., Gutteridge J.M.C. Free radicals in biology and medicine 2007, Oxford University Press, Oxford, United Kingdom. 4th ed.
33. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600.
34. Shah A.M., Mann D.L. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011, 378:704-712.
35. Santos C.X., Anilkumar N., Zhang M., Brewer A.C., Shah A.M. Redox signaling in cardiac myocytes. Free Radic Biol Med 2011, 50:777-793.
36. Ago T., Liu T., Zhai P., Chen W., Li H., Molkentin J.D., et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 2008, 133:978-993.
37. Haworth R.S., Stathopoulou K., Candasamy A.J., Avkiran M. Neurohormonal regulation of cardiac histone deacetylase 5 nuclear localization by phosphorylation-dependent and phosphorylation-independent mechanisms. Circ Res 2012, 110:1585-1595.
38. Bendall J.K., Cave A.C., Heymes C., Gall N., Shah A.M. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002, 105:293-296.
39. Satoh M., Ogita H., Takeshita K., Mukai Y., Kwiatkowski D.J., Liao J.K. Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A 2006, 103:7432-7437.
40. Nakagami H., Takemoto M., Liao J.K. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003, 35:851-859.
41. Hingtgen S.D., Tian X., Yang J., Dunlay S.M., Peek A.S., Wu Y., et al. Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol Genomics 2006, 26:180-191.
42. Izumiya Y., Kim S., Izumi Y., Yoshida K., Yoshiyama M., Matsuzawa A., et al. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res 2003, 93:874-883.
43. Hirotani S., Otsu K., Nishida K., Higuchi Y., Morita T., Nakayama H., et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002, 105:509-515.
44. Aikawa R., Nagai T., Tanaka M., Zou Y., Ishihara T., Takano H., et al. Reactive oxygen species in mechanical stress-induced cardiac hypertrophy. Biochem Biophys Res Commun 2001, 289:901-907.
45. Kuster G.M., Pimentel D.R., Adachi T., Ido Y., Brenner D.A., Cohen R.A., et al. Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. Circulation 2005, 111:1192-1198.
46. Pimentel D.R., Adachi T., Ido Y., Heibeck T., Jiang B., Lee Y., et al. Strain-stimulated hypertrophy in cardiac myocytes is mediated by reactive oxygen species-dependent Ras S-glutathiolation. J Mol Cell Cardiol 2006, 41:613-622.
47. Byrne J.A., Grieve D.J., Bendall J.K., Li J.M., Gove C., Lambeth J.D., et al. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 2003, 93:802-805.
48. Sciarretta S., Zhai P., Shao D., Zablocki D., Nagarajan N., Terada L.S., et al. Activation of NADPH oxidase 4 in the endoplasmic reticulum promotes cardiomyocyte autophagy and survival during energy stress through the protein kinase RNA-activated-like endoplasmic reticulum kinase/eukaryotic initiation factor 2alpha/activating transcription factor 4 pathway. Circ Res 2013, 113:1253-1264.
49. Zhang M., Brewer A.C., Schroder K., Santos C.X., Grieve D.J., Wang M., et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A 2010, 107:18121-18126.
50. Nlandu Khodo S., Dizin E., Sossauer G., Szanto I., Martin P.Y., Feraille E., et al. NADPH-oxidase 4 protects against kidney fibrosis during chronic renal injury. J Am Soc Nephrol 2012, 23:1967-1976.
51. Schroder K., Zhang M., Benkhoff S., Mieth A., Pliquett R., Kosowski J., et al. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 2012, 110:1217-1225.
52. Brewer A.C., Murray T.V., Arno M., Zhang M., Anilkumar N.P., Mann G.E., et al. Nox4 regulates Nrf2 and glutathione redox in cardiomyocytes in vivo. Free Radic Biol Med 2011, 51:205-215.
53. Zhang M., Perino A., Ghigo A., Hirsch E., Shah A.M. NADPH oxidases in heart failure: poachers or gamekeepers?. Antioxid Redox Signal 2013, 18:1024-1041.
54. Kuroda J., Ago T., Matsushima S., Zhai P., Schneider M.D., Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A 2010, 107:15565-15570.
55. Pouyssegur J., Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. Biol Chem 2006, 387:1337-1346.
56. Burgoyne J.R., Madhani M., Cuello F., Charles R.L., Brennan J.P., Schroder E., et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 2007, 317:1393-1397.
57. Wagner S., Rokita A.G., Anderson M.E., Maier L.S. Redox regulation of sodium and calcium handling. Antioxid Redox Signal 2013, 18:1063-1077.
58. Brennan J.P., Bardswell S.C., Burgoyne J.R., Fuller W., Schroder E., Wait R., et al. Oxidant-induced activation of type I protein kinase A is mediated by RI subunit interprotein disulfide bond formation. J Biol Chem 2006, 281:21827-21836.
59. Erickson J.R., Joiner M.L., Guan X., Kutschke W., Yang J., Oddis C.V., et al. A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 2008, 133:462-474.
60. He B.J., Joiner M.L., Singh M.V., Luczak E.D., Swaminathan P.D., Koval O.M., et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med 2011, 17:1610-1618.
61. Purohit A., Rokita A.G., Guan X., Chen B., Koval O.M., Voigt N., et al. Oxidized CaMKII triggers atrial fibrillation. Circulation 2013, 128:1748-1757.
62. Luo M., Guan X., Luczak E.D., Lang D., Kutschke W., Gao Z., et al. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. J Clin Invest 2013, 123:1262-1274.
63. Toischer K., Rokita A.G., Unsold B., Zhu W., Kararigas G., Sossalla S., et al. Differential cardiac remodeling in preload versus afterload. Circulation 2010, 122:993-1003.
64. Zima A.V., Blatter L.A. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006, 71:310-321.
65. Terentyev D., Gyorke I., Belevych A.E., Terentyeva R., Sridhar A., Nishijima Y., et al. Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum Ca2+ leak in chronic heart failure. Circ Res 2008, 103:1466-1472.
66. Cheong E., Tumbev V., Abramson J., Salama G., Stoyanovsky D.A. Nitroxyl triggers Ca2+ release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium 2005, 37:87-96.
67. Tocchetti C.G., Wang W., Froehlich J.P., Huke S., Aon M.A., Wilson G.M., et al. Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res 2007, 100:96-104.
68. Sag C.M., Wolff H.A., Neumann K., Opiela M.K., Zhang J., Steuer F., et al. Ionizing radiation regulates cardiac Ca handling via increased ROS and activated CaMKII. Basic Res Cardiol 2013, 108:385.
69. Sag C.M., Kohler A.C., Anderson M.E., Backs J., Maier L.S. CaMKII-dependent SR Ca leak contributes to doxorubicin-induced impaired Ca handling in isolated cardiac myocytes. J Mol Cell Cardiol 2011, 51:749-759.
70. Prosser B.L., Ward C.W., Lederer W.J. X-ROS signaling: rapid mechano-chemo transduction in heart. Science 2011, 333:1440-1445.
71. Sanchez G., Pedrozo Z., Domenech R.J., Hidalgo C., Donoso P. Tachycardia increases NADPH oxidase activity and RyR2 S-glutathionylation in ventricular muscle. J Mol Cell Cardiol 2005, 39:982-991.
72. Sivakumaran V., Stanley B.A., Tocchetti C.G., Ballin J.D., Caceres V., Zhou L., et al. HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization. Antioxid Redox Signal 2013, 19:1185-1197.
73. Xu K.Y., Zweier J.L., Becker L.C. Hydroxyl radical inhibits sarcoplasmic reticulum Ca(2+)-ATPase function by direct attack on the ATP binding site. Circ Res 1997, 80:76-81.
74. Goldhaber J.I. Free radicals enhance Na+/Ca2+ exchange in ventricular myocytes. Am J Physiol 1996, 271:H823-H833.
75. Gill J.S., McKenna W.J., Camm A.J. Free radicals irreversibly decrease Ca2+ currents in isolated guinea-pig ventricular myocytes. Eur J Pharmacol 1995, 292:337-340.
76. Kassmann M., Hansel A., Leipold E., Birkenbeil J., Lu S.Q., Hoshi T., et al. Oxidation of multiple methionine residues impairs rapid sodium channel inactivation. Pflugers Arch 2008, 456:1085-1095.
77. Sumandea M.P., Steinberg S.F. Redox signaling and cardiac sarcomeres. J Biol Chem 2011, 286:9921-9927.
78. Grutzner A., Garcia-Manyes S., Kotter S., Badilla C.L., Fernandez J.M., Linke W.A. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J 2009, 97:825-834.
79. Gao W.D., Murray C.I., Tian Y., Zhong X., DuMond J.F., Shen X. et al. Nitroxyl-mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. Circ Res 2012, 111:1002-1011.
80. Sano M., Minamino T., Toko H., Miyauchi H., Orimo M., Qin Y., et al. p53-Induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 2007, 446:444-448.
81. Krishnan J., Suter M., Windak R., Krebs T., Felley A., Montessuit C., et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab 2009, 9:512-524.
82. Craige S.M., Chen K., Pei Y., Li C., Huang X., Chen C., et al. NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation 2011, 124:731-740.
83. Jaba I.M., Zhuang Z.W., Li N., Jiang Y., Martin K.A., Sinusas A.J., et al. NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J Clin Invest 2013, 123:1718-1731.
84. Creemers E.E., Pinto Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011, 89:265-272.
85. Weber K.T., Sun Y., Bhattacharya S.K., Ahokas R.A., Gerling I.C. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 2013, 10:15-26.
86. Koitabashi N., Danner T., Zaiman A.L., Pinto Y.M., Rowell J., Mankowski J., et al. Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J Clin Invest 2011, 121:2301-2312.
87. Zeisberg E.M., Tarnavski O., Zeisberg M., Dorfman A.L., McMullen J.R., Gustafsson E., et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952-961.
88. Johar S., Cave A.C., Narayanapanicker A., Grieve D.J., Shah A.M. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 2006, 20:1546-1548.
89. Grieve D.J., Byrne J.A., Siva A., Layland J., Johar S., Cave A.C., et al. Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol 2006, 47:817-826.
90. Looi Y.H., Grieve D.J., Siva A., Walker S.J., Anilkumar N., Cave A.C., et al. Involvement of Nox2 NADPH oxidase in adverse cardiac remodeling after myocardial infarction. Hypertension 2008, 51:319-325.
91. Doerries C., Grote K., Hilfiker-Kleiner D., Luchtefeld M., Schaefer A., Holland S.M., et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007, 100:894-903.
92. Nakamura T., Kataoka K., Fukuda M., Nako H., Tokutomi Y., Dong Y.F., et al. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension 2009, 54:544-551.
93. Murdoch CE C.A., Zeng L., Yu B., Ivetic A., Walker S.J., Vanhoutte D., et al. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through pro-inflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol 2014, [in press].
94. Engberding N., Spiekermann S., Schaefer A., Heineke A., Wiencke A., Muller M., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation 2004, 110:2175-2179.
95. Sun Y. Oxidative stress and cardiac repair/remodeling following infarction. Am J Med Sci 2007, 334:197-205.
96. Krijnen P.A., Meischl C., Hack C.E., Meijer C.J., Visser C.A., Roos D., et al. Increased Nox2 expression in human cardiomyocytes after acute myocardial infarction. J Clin Pathol 2003, 56:194-199.
97. Sia Y.T., Lapointe N., Parker T.G., Tsoporis J.N., Deschepper C.F., Calderone A., et al. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation 2002, 105:2549-2555.
98. Masano T., Kawashima S., Toh R., Satomi-Kobayashi S., Shinohara M., Takaya T., et al. Beneficial effects of exogenous tetrahydrobiopterin on left ventricular remodeling after myocardial infarction in rats: the possible role of oxidative stress caused by uncoupled endothelial nitric oxide synthase. Circ J 2008, 72:1512-1519.
99. Rastaldo R., Pagliaro P., Cappello S., Penna C., Mancardi D., Westerhof N., et al. Nitric oxide and cardiac function. Life Sci 2007, 81:779-793.
100. Fauconnier J., Meli A.C., Thireau J., Roberge S., Shan J., Sassi Y., et al. Ryanodine receptor leak mediated by caspase-8 activation leads to left ventricular injury after myocardial ischemia-reperfusion. Proc Natl Acad Sci U S A 2011, 108:13258-13263.
101. Lonn E., Bosch J., Yusuf S., Sheridan P., Pogue J., Arnold J.M., et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005, 293:1338-1347.
102. Kuhns D.B., Alvord W.G., Heller T., Feld J.J., Pike K.M., Marciano B.E., et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010, 363:2600-2610.
103. Moens A.L., Takimoto E., Tocchetti C.G., Chakir K., Bedja D., Cormaci G., et al. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation 2008, 117:2626-2636.
104. Cunnington C., Van Assche T., Shirodaria C., Kylintireas I., Lindsay A.C., Lee J.M., et al. Systemic and vascular oxidation limits the efficacy of oral tetrahydrobiopterin treatment in patients with coronary artery disease. Circulation 2012, 125:1356-1366.
105. Dai D.F., Chen T., Szeto H., Nieves-Cintron M., Kutyavin V., Santana L.F., et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol 2011, 58:73-82.
106. Graham D., Huynh N.N., Hamilton C.A., Beattie E., Smith R.A., Cocheme H.M., et al. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension 2009, 54:322-328.
107. Samuel S.M., Thirunavukkarasu M., Penumathsa S.V., Koneru S., Zhan L., Maulik G., et al. Thioredoxin-1 gene therapy enhances angiogenic signaling and reduces ventricular remodeling in infarcted myocardium of diabetic rats. Circulation 2010, 121:1244-1255.
108. Kannan S., Muthusamy V.R., Whitehead K.J., Wang L., Gomes A.V., Litwin S.E., et al. Nrf2 deficiency prevents reductive stress-induced hypertrophic cardiomyopathy. Cardiovasc Res 2013, 100:63-73.
109. Erickson J.R., He B.J., Grumbach I.M., Anderson M.E. CaMKII in the cardiovascular system: sensing redox states. Physiol Rev 2011, 91:889-915.